TAp63α induces apoptosis by activating signaling via death receptors and mitochondria

EMBO Journal

Volumn 24, Issue 13, 2005, Pages 2458-2471

  Gressner, Olav ^a   Schilling, Tobias ^a   Lorenz, Katja ^a   Schleithoff, Elisa Schulze ^a   Koch, Andreas ^a   Schulze Bergkamen, Henning ^b   Lena, Anna Maria ^c   Candi, Eleonora ^c   Terrinoni, Alessandro ^c   Catani, Maria Valeria ^c   Oren, Moshe ^d   Melino, Gerry ^e   Krammer, Peter H ^b   Stremmel, Wolfgang ^a   Müller, Martina ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c CATHOLIC UNIVERSITY   (Italy)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Apoptosis; CD95; Chemosensitivity; TAp63; TRAIL

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BLEOMYCIN; CISPLATIN; DEATH ASSOCIATED PROTEIN 3; DEATH RECEPTOR; DOXORUBICIN; FAS ANTIGEN; MITOXANTRONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL2L11; PROTEIN P53; PROTEIN RAD9; PROTEIN TAP63ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APAF1 PROTEIN, HUMAN; APOPTOSIS REGULATORY PROTEIN; BAX PROTEIN, HUMAN; BCL 2 BINDING PROTEIN, BIM; BCL-2-BINDING PROTEIN, BIM; CASPASE; CELL CYCLE PROTEIN; DAP3 PROTEIN, HUMAN; DNA BINDING PROTEIN; MEMBRANE PROTEIN; ONCOPROTEIN; PHOSPHOPROTEIN; PROTEIN; RIBOSOME PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TP73L PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; INTRON; MITOCHONDRION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; TRANSACTIVATION; BIOSYNTHESIS; DNA MICROARRAY; DRUG EFFECT; ENZYME ACTIVATION; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENES, TUMOR SUPPRESSOR; HUMANS; MEMBRANE PROTEINS; MITOCHONDRIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPROTEINS; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TUMOR NECROSIS FACTOR; RIBOSOMAL PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 22744459472     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.emboj.7600708     Document Type: Article

References (48)

1. Agami R, Blandino G, Oren M, Shaul Y (1999) Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 399: 809
2. Ben Yehoyada M, Ben Dor I, Shaul Y (2003) c-Abl tyrosine kinase selectively regulates p73 nuclear matrix association. J Biol Chem 278: 34475-34482
3. Benchimol S (2004) p53 - an examination of sibling support in apoptosis control. Cancer Cell 6: 3-4
4. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29: 365-371
5. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP, Romani M (2002) Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9: 246-251
6. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, McKeon F, Brunner HG, van Bokhoven H (1999) Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99: 143-153
7. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, Levrero M (2002) DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 9: 175-186
8. Dhein J, Daniel PT, Trauth BC, Oehm A, Möller P, Krammer PH (1992) Induction of apoptosis by monoconal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 149: 3166-3173
9. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Natl Genet 1: 45-49
10. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564
11. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11 (Suppl 1): S86-S96
12. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M, Wang JY (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806-809
13. Gonzalez S, Prives C, Cordon-Cardo C (2003) p73alpha regulation by Chk1 in response to DNA damage. Mol Cell Biol 23: 8161-8171
14. Gupta S, Radha V, Furukawa Y, Swarup G (2001) Direct transcriptional activation of human caspase-1 by tumor suppressor p53. J Biol Chem 276: 10585-10588
15. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514
16. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG (2003) Chemosensitivity linked to p73 function. Cancer Cell 3: 403-410
17. Kissil JL, Cohen O, Raveh T, Kimchi A (1999) Structure-function analysis of an evolutionary conserved protein, DAP3, which mediates TNF-alpha- and Fas-induced cell death. EMBO J 18: 353-362
18. Lee SY, Choi Y (1997) TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J Exp Med 185: 1275-1285
19. Liedtke C, Groger N, Manns MP, Trautwein C (2003) The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism. J Biol Chem 278: 27593-27604
20. Liu X, Yue P, Khuri FR, Sun SY (2004) p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 64: 5078-5083
21. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, Knight RA, Green DR, Thompson C, Vousden KH (2004) p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279: 8076-8083
22. Melino G, De Laurenzi V, Vousden KH (2002) p73: friend or foe in tumorigenesis. Nat Rev Cancer 2: 605-615
23. Melino G, Lu X, Gasco M, Crook T, Knight RA (2003) Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 28: 663-670
24. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713
25. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299
26. Miyazaki T, Reed JC (2001) A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteins. Nat Immunol 2: 493-500
27. Moll UM, Slade N (2004) p63 and p73: roles in development and tumor formation. Mol Cancer Res 2: 371-386
28. Mukamel Z, Kimchi A (2004) Death-associated protein 3 localizes to the mitochondria and is involved in the process of mitochondrial fragmentation during cell death. J Biol Chem 279: 36732-36738
29. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 403-413
30. Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188: 2033-2045
31. Nicoletti I, Migliorati G, Paggliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279
32. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53 [see comments] [published erratum appears in Nat Med 1998 Sep;4(9):982]. Nat Med 4: 839-843
33. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, Ponzin D, McKeon F, De Luca M (2001) p63 identifies keratinocyte stem cells. Proc Natl Acad Sci USA 98: 3156-3161
34. Petitjean A, Cavard C, Shi H, Tribollet V, Hainaut P, Caron dF (2005) The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells. Oncogene 24: 512-519
35. Senoo M, Manis JP, Alt FW, McKeon F (2004) p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell 6: 85-89
36. The Tumor Analysis Best Practices Working Group (2004) Expression profiling-best practices for data generation and interpretation in clinical trials. Nat Rev Genet 5: 229-237
37. Trauth BC, Klas C, Peters AJM, Matzku S, Möller P, Falk W, Debatin KM, Krammer PH (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301-305
38. Vousden KH (2000) p53: death star. Cell 103: 691-694
39. Wada N, Matsumura M, Ohba Y, Kobayashi N, Takizawa T, Nakanishi Y (1995) Transcription stimulation of the Fas-encoding gene by nuclear factor for interleukin-6 expression upon influenza virus infection. J Biol Chem 270: 18007-18012
40. Westfall MD, Pietenpol JA (2004) p63: molecular complexity in development and cancer. Carcinogenesis 25: 857-864
41. White E, Prives C (1999) DNA damage enables p73. Nature 399: 734-737
42. Wu G, Osada M, Guo Z, Fomenkov A, Begum S, Zhao M, Upadhyay S, Xing M, Wu F, Moon C, Westra WH, Koch WM, Mantovani R, Califano JA, Ratovitski E, Sidransky D, Trink B (2005) DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Res 65: 758-766
43. Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, El-Deiry WS (1997) KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene [letter]. Nat Genet 17: 141-143
44. Yang A, Kaghad M, Caput D, McKeon F (2002) On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 18: 90-95
45. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718
46. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D (1999) p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399: 814-817
47. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM (2002) DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196: 765-780
48. Zuliani T, Duval R, Jayat C, Schnebert S, Andre P, Dumas M, Ratinaud MH (2003) Sensitive and reliable JC-1 and TOTO-3 double staining to assess mitochondrial transmembrane potential and plasma membrane integrity: interest for cell death investigations. Cytometry 54A: 100-108